[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349511-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349511-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-antiretroviral-therapy-and-long-term-cancer-risk-in-hiv-9-year-outcomes-from-the-start-randomized-trial-clinical-study-results","Early antiretroviral therapy and long-term cancer risk in HIV - 9-year outcomes from the START randomized trial - clinical study results","","Antiretroviral therapy (ART) lowers cancer risk in people with HIV, yet the long-term effect of starting ART immediately on infection-related and infection-unrelated cancers has been unclear. The START trial randomized 4684 ART-naïve adults with CD4+ counts >500 cells/mm3 to immediate vs deferred ART (until CD4+ \u003C350). Follow-up continued through 2021, with analysis by infection status and pre- and post-2016 periods after unblinding. Over 9 years, overall cancer risk was reduced (HR 0.50), especially infection-related cancers, while infection-unrelated cancers showed no significant difference.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-antiretroviral-therapy-and-long-term-cancer-risk-in-hiv-9-year-outcomes-from-the-start-randomized-trial-clinical-study-results/349511/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-antiretroviral-therapy-and-long-term-cancer-risk-in-hiv-9-year-outcomes-from-the-start-randomized-trial-clinical-study-results/349511.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main question about ART timing in the START trial analysis?","Question",{"text":63,"@type":64},"Whether immediate ART initiation, compared with deferred initiation, changes long-term risk of infection-related and infection-unrelated cancers in people with HIV.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants assigned to immediate versus deferred ART?",{"text":68,"@type":64},"ART-naïve adults with CD4+ counts >500 cells/mm3 were randomized to start ART immediately or defer ART until CD4+ declined below 350 cells/mm3 or an AIDS-related condition occurred.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find after a median follow-up of 9 years?",{"text":72,"@type":64},"Overall cancer risk was lower with immediate ART (HR 0.50). The reduction was strongest pre-2016 for infection-related cancers, while infection-unrelated cancers did not differ significantly between arms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349511,1790537915,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Ramaswami et al. BMC Cancer (2026) 26:963 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16188-8](https://doi.org/10.1186/s12885-026-16188-8)  \nRESEARCH Open Access  \nEarly antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial  \nRamya Ramaswami 1*, Jacqueline A. Nordwall2, Duncan Gilbert3, Ellen Kitchell4, Alisa Timiryasova5, Ronald Mitsuyasu6, Andrew N. Phillips7, Jens Lundgren5 and Sophie Grabar8  \nAbstract  \nBackground Antiretroviral therapy (ART) reduces cancer risk in people with HIV (PWH) but the long-term impact of immediate ART initiation on infection-related and infection-unrelated cancers remains unclear.  \nMethods In the Strategic Timing of Antiretroviral Treatment (START) trial, 4684 ART-naïve adult PWH with CD4 + T-cell count above 500 cells/mm3 were randomized to immediate or deferred ART initiation arms (i. e., until CD4 + T-cells below 350 cells/mm3) . In May 2015, unblinding revealed a 74% reduction in infection-related cancer risk in the immediate arm. Post-2016, participants in the deferred arm were recommended to start ART, and follow-up continued through 2021. This analysis evaluates cancer incidence (by infection-related and infection-unrelated diagnoses) between the treatment arms by time-period (overall, pre-2016 and post-2016) .  \nResults Over a median follow-up of 9 years, 120 participants were diagnosed with cancer. The overall hazard ratio (HR) for cancer risk in the immediate versus deferred arms was 0.50 (95% CI: 0.34 to 0 . 73; p \u003C 0. 001) . Pre-2016, the HR (immediate vs. deferred) was 0.33 (95% CI: 0.19 to 0 . 60; P \u003C 0. 001), while post-2016, it was 0.69 (95% CI: 0.42 to 1. 13; P = 0 . 14), and P = 0.062 for the difference. For infection-related cancers in pre-2016 the HR was 0.24 (95% CI: 0.11 to 0. 55; P \u003C 0. 001) and post-2016, HR was 0.53 (95% CI: 0.23 to 1. 18; P = 0 . 12) and P = 0.18 for the difference. For infectionunrelated cancers, there was no significant difference in HR between immediate and deferred arms in either time period.  \nConclusion Immediate ART initiation significantly reduces infection-related cancer risk in PWH that persists long-term.  \nClinical trial registration NCT00867048 .  \nKeywords HIV-associated cancers, Infection-related cancer, ART, START, Kaposi sarcoma  \n*Correspondence:  \nRamya Ramaswami  \n[ramya.ramaswami@nih.gov](ramya.ramaswami@nih.gov)  \n1HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, 6N106, Bethesda, MD 20892, USA  \n2Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, MN, USA  \n3MRC Clinical Trials Unit at University College London, London, UK  \n4Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern, Dallas, TX, USA  \n5CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, and Department of Clinical Medicine, Copenhagen, Denmark  \n6University of California Los Angeles Clinical AIDS Research and Education Center, Los Angeles, CA, USA  \n7Institute for Global Health, University College London, London, UK 8Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie Et de Santé Publique, AP-HP, Hôpital St Antoine, Paris 75012, France  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. ","cbCaigRMddo98TGo","https://ap.wps.com/l/cbCaigRMddo98TGo","pdf",1866675,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the main question about ART timing in the START trial analysis?\",\"answer\":\"Whether immediate ART initiation, compared with deferred initiation, changes long-term risk of infection-related and infection-unrelated cancers in people with HIV.\"},{\"question\":\"How were participants assigned to immediate versus deferred ART?\",\"answer\":\"ART-naïve adults with CD4+ counts \\u003e500 cells/mm3 were randomized to start ART immediately or defer ART until CD4+ declined below 350 cells/mm3 or an AIDS-related condition occurred.\"},{\"question\":\"What did the study find after a median follow-up of 9 years?\",\"answer\":\"Overall cancer risk was lower with immediate ART (HR 0.50). The reduction was strongest pre-2016 for infection-related cancers, while infection-unrelated cancers did not differ significantly between arms.\"}]","Early antiretroviral therapy and long-term cancer risk in HIV - 9-year outcomes from the START randomized trial - clinical study results | PDF",1790084025,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b59099d1e9858fa619ec706e3504e97.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21335f917f10b7a5c2458797fc1b4585.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad5f2135e651357a3d8e1e18fc59a059.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe4e7dbdd79985b27571253cccf69187.webp",980,1306]